JOHN M LEONARD
CIK 1563584 · President and CEO · last filed 2026-08-24
JOHN M LEONARD is a President and CEO who has filed 69 SEC Form 4 insider transactions across 6 companies since 2013. The most recent filing shows the insider sold $286.8K of NTLA on Aug 24, 2026. Across all open-market trades the lifetime net is −$60.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $49.7M across reported positions. 6 SEC filings were submitted jointly with AbbVie Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$49.68M
6
69
-$60.76M
Filer Profile
40 ERIE STREET, SUITE 130
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NTLA | President and CEO | 1,208,264 | $12.74 | $15.39M | -$54.97M | 39 | 2026-08-24 |
| IQV | Director | 16,946 | $267.77 | $4.54M | -$3.09M | 10 | 2026-04-27 |
| CHIMERIX INC (CMRX) Delisted | Director | 4,000 | $8.54 | $34.2K | $138.2K | 6 | 2017-06-29 |
| Q | Director | 4,702 | $120.47 | $566.4K | $0 | 4 | 2017-05-25 |
| Vitae Pharmaceuticals, Inc (VTAE) Delisted | Director | — | — | — | $0 | 3 | 2016-10-25 |
| ABBV | SVP, Chief Scientific Officer | 113,793 | $256.46 | $29.18M | -$2.84M | 5 | 2013-03-19 |
Recent Filings
69 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-24 | NTLA | Sell (S) | −22,675 | -$286.8K | EDGAR |
| 2026-08-20 | NTLA | Notice (144) | −22,675 | -$293.6K | EDGAR |
| 2026-04-27 | IQV | Grant (A) | +1,571 | $0 | EDGAR |
| 2026-03-03 | NTLA | Grant (A) | +156,400 | $0 | EDGAR |
| 2026-01-07 | NTLA | Sell (S) | −34,146 | -$314.5K | EDGAR |
| 2025-12-12 | NTLA | Mixed | −29,630 | -$436.7K | EDGAR |
| 2025-12-11 | NTLA | Notice (144) | −88,146 | -$822.4K | EDGAR |
| 2025-04-25 | IQV | Grant (A) | +1,592 | $0 | EDGAR |
| 2025-03-04 | NTLA | Grant (A) | +136,000 | $0 | EDGAR |
| 2025-01-07 | NTLA | Sell (S) | −26,807 | -$326.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.